ALLO-213

N/A

Report date: 2023/04/23 17:01:03

Base Information

Drug NameALLO-213

Drug Alias NameALLO-213

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionDelta-like protein 3 inhibitors

TargetsDelta-like protein 3

Therapy Area/IndicationsSmall Cell Lung Carcinoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAllogene Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAllogene Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSmall Cell Lung Carcinoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A